Sleep disorders as a possible predisposing attack factor in neuromyelitis optica spectrum disorder (NMOSD): A case-control study

Rabi, Samaneh Haji Molla; Shahmirzaei, Shaghayegh; Sahraian, Mohammad Ali; Mozdabadi, Razieh Sadat Kazemi; Aliabadi, Hossein Rezaei; Gheini, Mohammad Reza; Majidi, Fazeleh; Moghadasi, Abdorreza Naser

doi:10.1016/j.clineuro.2021.106606

Cited by 9 publications

(2 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies evaluating environmental factors such as vitamin D levels, dietary intake, and sleep patterns were inconclusive. 22 37 38 Several authors reported temporal association of the inaugural attack with different infections and, less commonly, vaccinations. 39 40 To date, there is no evidence of a clear association of NMOSD attacks with specific infections.…”

Section: Epidemiologymentioning

confidence: 99%

Neuromyelitis optica spectrum disorders: a review with a focus on children and adolescents

et al. 2023

View full text Add to dashboard Cite

Neuromyelitis optica spectrum disorder (NMOSD) is a rare and severe inflammatory disorder of the central nervous system (CNS). It is strongly associated with anti-aquaporin 4 antibodies (AQP4-IgG), and it mainly affects young women from non-white ethnicities. However, ∼ 5 to 10% of all cases have onset during childhood. Children and adolescents share the same clinical, radiologic, and laboratory presentation as adults. Thus, the same NMOSD diagnostic criteria are also applied to pediatric-onset patients, but data on NMOSD in this population is still scarce. In seronegative pediatric patients, there is a high frequency of the antibody against myelin oligodendrocyte glycoprotein (MOG-IgG) indicating another disease group, but the clinical distinction between these two diseases may be challenging. Three drugs (eculizumab, satralizumab, and inebilizumab) have been recently approved for the treatment of adult patients with AQP4-IgG-positive NMOSD. Only satralizumab has recruited adolescents in one of the two pivotal clinical trials. Additional clinical trials in pediatric NMOSD are urgently required to evaluate the safety and efficacy of these drugs in this population.

show abstract

Section: Epidemiologymentioning

confidence: 99%

Neuromyelitis optica spectrum disorders: a review with a focus on children and adolescents

et al. 2023

View full text Add to dashboard Cite

show abstract

“…All the scales used in the present study have been utilized in previous NMOSD studies (13,14,(22)(23)(24). All the Chinese versions of these scales have been validated previously (25)(26)(27)(28)(29).…”

Section: Quality Of Life Evaluation Of Nmosd Patientsmentioning

confidence: 99%

Impact of dysautonomic symptom burden on the quality of life in Neuromyelitis optica spectrum disorder patients

Yang

Xie

et al. 2022

Preprint

View full text Add to dashboard Cite

Background The aim of this study was to investigate the clinical risk factors of dysautonomic symptom burden in neuromyelitis optica spectrum disorder (NMOSD), and its impact on patients’ quality of life. Methods A total of 63 NMOSD patients and healthy controls were enrolled. All participants completed the Composite Autonomic Symptom Score 31 (COMPASS-31) to screen for symptoms of autonomic dysfunction. A comprehensive clinical evaluation was performed in NMOSD patients, including disease characteristics and composite evaluations of life status, including quality of life, anxiety/depression, sleep, and fatigue. Correlated factors of dysautonomic symptoms and quality of life were analyzed. Results The score of COMPASS-31 in the NMOSD group was 17.2 ± 10.3, significantly higher than that in healthy controls (P = 0.002). In NMOSD patients, the higher COMPASS-31 score was correlated with more attacks (r = 0.49, P < 0.001), longer disease duration (r = 0.52, P < 0.001), severer disability (r = 0.50, P < 0.001), more thoracic cord lesions (r = 0.29, P = 0.02), more total spinal cord lesions (r = 0.35, P = 0.005), severer anxiety (r = 0.55, P < 0.001), severer depression (r = 0.48, P < 0.001), severer sleep disturbances (r = 0.59, P < 0.001), and severer fatigue (r = 0.56, P < 0.001). The disability, total spinal cord lesions and fatigue were revealed to be independently associated factors. Further analysis revealed that the COMPASS-31 score was the independently correlated with score of all the domains of patients’ quality of life scale (P < 0.05). Conclusions Dysautonomic symptom burden is correlated with decreased quality of life and certain clinical characteristics such as disability, spinal cord lesions and fatigue in NMOSD patients. Investigation and proper management of autonomic dysfunction may help to improve the quality of life in patients with NMOSD.

show abstract

Sleep in multiple sclerosis and neuromyelitis optica spectrum disorder—the SEMN study

Sousa

Almeida²,

Takano

et al. 2023

Sleep Breath

View full text Add to dashboard Cite

Sleep disorders as a possible predisposing attack factor in neuromyelitis optica spectrum disorder (NMOSD): A case-control study

Cited by 9 publications

References 41 publications

Neuromyelitis optica spectrum disorders: a review with a focus on children and adolescents

Neuromyelitis optica spectrum disorders: a review with a focus on children and adolescents

Impact of dysautonomic symptom burden on the quality of life in Neuromyelitis optica spectrum disorder patients

Sleep in multiple sclerosis and neuromyelitis optica spectrum disorder—the SEMN study

Contact Info

Product

Resources

About